reMYND is a clinical-stage biopharma built on a proprietary drug-discovery platform that identifies novel mechanisms, targets and first-in-class small molecules. Its most advanced program, ReS19-T, is an investigational compound for Alzheimer’s that entered the clinic in Q4 2020 and has shown restoration of synaptic plasticity in animal models. The company is also developing ReS39 for diabetes; animal studies indicate increased endogenous insulin production and durable effects on blood glucose and end-organ protection. reMYND operates a dedicated CRO that tests pharmacokinetics, pharmacodynamics and efficacy in proprietary CNS animal models for a global client base. Proceeds from the recently extended Series B will fund completion of clinical proof-of-concept trials for both the Alzheimer’s and diabetes programs in 2022 and support continued clinical advancement. The company has signaled plans to engage potential pharma partners and international investors to advance programs beyond proof-of-concept.

Total raised

$15M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2021